These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 11302820)

  • 1. Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations.
    Wang H; Dzink-Fox JL; Chen M; Levy SB
    Antimicrob Agents Chemother; 2001 May; 45(5):1515-21. PubMed ID: 11302820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'Supermutators' found amongst highly levofloxacin-resistant E. coli isolates: a rapid protocol for the detection of mutation sites.
    Zayed AA; Essam TM; Hashem AG; El-Tayeb OM
    Emerg Microbes Infect; 2015 Jan; 4(1):e4. PubMed ID: 26038761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of the marA or soxS regulatory gene in clinical topoisomerase mutants of Escherichia coli.
    Oethinger M; Podglajen I; Kern WV; Levy SB
    Antimicrob Agents Chemother; 1998 Aug; 42(8):2089-94. PubMed ID: 9687412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic characterization of phenicol-resistant Escherichia coli and role of wild-type repressor/regulator gene (acrR) on phenicol resistance.
    Yaqoob M; Wang LP; Kashif J; Memon J; Umar S; Iqbal MF; Fiaz M; Lu CP
    Folia Microbiol (Praha); 2018 Jul; 63(4):443-449. PubMed ID: 29307119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of mutations in marRAB or soxRS in acrB-overexpressing fluoroquinolone-resistant clinical and veterinary isolates of Escherichia coli.
    Webber MA; Piddock LJ
    Antimicrob Agents Chemother; 2001 May; 45(5):1550-2. PubMed ID: 11302826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump.
    Oethinger M; Kern WV; Jellen-Ritter AS; McMurry LM; Levy SB
    Antimicrob Agents Chemother; 2000 Jan; 44(1):10-3. PubMed ID: 10602715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced expression of the multidrug efflux pumps AcrAB and AcrEF associated with insertion element transposition in Escherichia coli mutants Selected with a fluoroquinolone.
    Jellen-Ritter AS; Kern WV
    Antimicrob Agents Chemother; 2001 May; 45(5):1467-72. PubMed ID: 11302812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of an acrR mutation in multidrug resistance of in vitro-selected fluoroquinolone-resistant mutants of Salmonella enterica serovar Typhimurium.
    Olliver A; Vallé M; Chaslus-Dancla E; Cloeckaert A
    FEMS Microbiol Lett; 2004 Sep; 238(1):267-72. PubMed ID: 15336432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli.
    Kern WV; Oethinger M; Jellen-Ritter AS; Levy SB
    Antimicrob Agents Chemother; 2000 Apr; 44(4):814-20. PubMed ID: 10722475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of AcrR and ramA in fluoroquinolone resistance in clinical Klebsiella pneumoniae isolates from Singapore.
    Schneiders T; Amyes SG; Levy SB
    Antimicrob Agents Chemother; 2003 Sep; 47(9):2831-7. PubMed ID: 12936981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of high-level fluoroquinolone resistance in Escherichia coli O78:K80 isolated from turkeys.
    Giraud E; Leroy-Sétrin S; Flaujac G; Cloeckaert A; Dho-Moulin M; Chaslus-Dancla E
    J Antimicrob Chemother; 2001 Mar; 47(3):341-3. PubMed ID: 11222567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of transcriptional activators RamA and SoxS on expression of multidrug efflux pumps AcrAB and AcrEF in fluoroquinolone-resistant Salmonella Typhimurium.
    Zheng J; Cui S; Meng J
    J Antimicrob Chemother; 2009 Jan; 63(1):95-102. PubMed ID: 18984645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tigecycline Nonsusceptibility Occurs Exclusively in Fluoroquinolone-Resistant Escherichia coli Clinical Isolates, Including the Major Multidrug-Resistant Lineages O25b:H4-ST131-H30R and O1-ST648.
    Sato T; Suzuki Y; Shiraishi T; Honda H; Shinagawa M; Yamamoto S; Ogasawara N; Takahashi H; Takahashi S; Tamura Y; Yokota SI
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations That Enhance the Ciprofloxacin Resistance of Escherichia coli with qnrA1.
    Vinué L; Corcoran MA; Hooper DC; Jacoby GA
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1537-45. PubMed ID: 26711751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of fluoroquinolone resistance mechanisms and their correlation with the degree of resistance to clinically used fluoroquinolones among Escherichia coli isolates.
    Chang TM; Lu PL; Li HH; Chang CY; Chen TC; Chang LL
    J Chemother; 2007 Oct; 19(5):488-94. PubMed ID: 18073146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does mutation in gyrA and/or parC or efflux pump expression play the main role in fluoroquinolone resistance in Escherichia coli urinary tract infections?: A statistical analysis study.
    Shigemura K; Tanaka K; Yamamichi F; Shirakawa T; Miyake H; Fujisawa M
    Int J Antimicrob Agents; 2012 Dec; 40(6):516-20. PubMed ID: 23068598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of the AcrAB-TolC efflux pump to high-level fluoroquinolone resistance in Escherichia coli isolated from dogs and humans.
    Sato T; Yokota S; Okubo T; Ishihara K; Ueno H; Muramatsu Y; Fujii N; Tamura Y
    J Vet Med Sci; 2013 May; 75(4):407-14. PubMed ID: 23149545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the acrAB locus in organic solvent tolerance mediated by expression of marA, soxS, or robA in Escherichia coli.
    White DG; Goldman JD; Demple B; Levy SB
    J Bacteriol; 1997 Oct; 179(19):6122-6. PubMed ID: 9324261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli.
    Heisig P
    Antimicrob Agents Chemother; 1996 Apr; 40(4):879-85. PubMed ID: 8849244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis.
    Bebear CM; Renaudin J; Charron A; Renaudin H; de Barbeyrac B; Schaeverbeke T; Bebear C
    Antimicrob Agents Chemother; 1999 Apr; 43(4):954-6. PubMed ID: 10103208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.